Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection

Experimental Parasitology

Volumn 128, Issue 4, 2011, Pages 448-453

  Sánchez, Vanesa R ^a   Pitkowski, Martín N ^a   Fernández Cuppari, Anahí V ^a   Rodríguez, Facundo M ^a   Fenoy, Ignacio M ^a   Frank, Fernanda M ^b   Goldman, Alejandra ^a   Corral, Ricardo S ^c   Martin, Valentina ^a  

^a UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

C3H HeN mice; CpG ODN; GRA4; Recombinant protein based vaccine; ROP2; Th1 Th2 immune responses; Toxoplasma gondii

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; PROTEIN GRA4; PROTEIN ROP2; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXOPLASMOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; BRAIN; CYTOKINES; FEMALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; OLIGODEOXYRIBONUCLEOTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

ANIMALIA; MUS; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 79960560392     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.04.004     Document Type: Article

References (44)

1. Blackwell J.M., Roberts C.W., Alexander J. Influence of genes within the MHC on mortality and brain cyst development in mice infected with Toxoplasma gondii: kinetics of immune regulation in BALB H-2 congenic mice. Parasite Immunology 1993, 15:317-324.
2. Boothroyd J.C., Grigg M.E. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?. Current Opinion in Microbiology 2002, 5:438-442.
3. Boyle J.P., Rajasekar B., Saeij J.P., Ajioka J.W., Berriman M., Paulsen I., Roos D.S., Sibley L.D., White M.W., Boothroyd J.C. Just one cross appears capable of dramatically altering the population biology of a eukaryotic pathogen like Toxoplasma gondii. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10514-10519.
4. Brown C.R., Hunter C.A., Estes R.G., Beckmann E., Forman J., David C., Remington J.S., McLeod R. Definitive identification of a gene that confers resistance against toxoplasmosis. Immunology 1995, 85:419-428.
5. Buxton D., Innes K.E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology 1995, 110:S11-S16.
6. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature Biotechnology 2000, 18:509-514.
7. Corral R.S., Petray P.B. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine 2001, 19:234-242.
8. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., DiDonato J., Dziarski R., Akira S., Schoenberger S.P., Raz E. A subset of Toll-like receptor ligands induces crosspresentation by bone marrow-derived dendritic cells. Journal of Immunology 2003, 170:4102-4110.
9. Dennis V.A., Jefferson A., Singh S.R., Ganapamo F., Philipp M.T. Interleukin-10 antiinflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3. Infection and Immunity 2006, 74:5780-5789.
10. Dlugonska H. Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. Journal of Biomedicine and Biotechnology 2009, 2008:1-7.
11. Dziadek B., Gatkowska J., Brzostek A., Dziadek J., Dzitko K., Dlugonska H. Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. Experimental Parasitology 2009, 123:81-89.
12. Echeverria P.C., de Miguel N., Costas M., Angel S.O. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine 2006, 24:4102-4110.
13. Ellis R.D., Martin L.B., Shaffer D., Long C.A., Miura K., Fay M.P., Narum D.L., Zhu D., Mullen G.E., Mahanty S., Miller L.H., Durbin A.P. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS ONE 2010, 5:8787-8792.
14. El-Malky M., Shaohong L., Kumagai T., Yabu Y., Noureldin M.S., Saudy N., Maruyama H., Ohta N. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice. Microbiology and Immunology 2005, 49:639-646.
15. Escajadillo A., Frenkel J.K. Experimental toxoplasmosis and vaccine tests in Aotus monkeys. American Journal of Tropical Medicine and Hygiene 1991, 44:382-389.
16. Fernandez Cuppari A., Sanchez V.R., Ledesma B., Frank F.M., Goldman A., Angel S.O., Martin V. Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2008, 26:5040-5045.
17. Frank F.M., Petray P.B., Cazorla S.I., Muñoz M.C., Corral R.S., Malchiodi E.L. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003, 22:77-86.
18. Gazzinelli R.T., Hakim F.T., Hieny S., Shearer G.M., Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-γ production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. Journal of Immunology 1991, 146:286-292.
19. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
20. Iborra S., Parody N., Abanades D.R., Bonay P., Prates D., Novais F.O., Barral-Netto M., Alonso C., Soto M. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes and Infection 2008, 10:1133-1141.
21. Igarashi M., Kano F., Tamekuni K., Machado R.Z., Nawarro I.T., Vidotto O., Vidotto M.C., Garcia J.L. Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice. Experimental Parasitology 2008, 118:386-392.
22. Jongert E., Roberts C.W., Gargano N., Förster-Wald E., Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Memorias do Instituto Oswaldo Cruz 2009, 104:252-266.
23. Kang H., Remington J.S., Suzuki Y. Decreased resistance of B cell deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. Journal of Immunology 2000, 164:2629-2634.
24. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews 2004, 199:201-216.
25. Kringel H., Dubey J.P., Beshah E., Hecker R., Urban J.F. CpG oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii. Veterinary Parasitology 2004, 123:55-66.
26. Liu T., Matsuguchi T., Tsuboi N., Yajima T., Yoshikai Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infection and Immunity 2002, 70:6638-6645.
27. Liu S., Shi L., Cheng Y., Fan G., Ren H., Yuan Y. Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice. Parasitology Research 2009, 105:267-274.
28. Martin V., Supanitsky A., Echeverria P., Litwin S., Tanos T., De Roodt A., Guarnera E., Angel S.O. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clinical and Diagnostic Laboratory Immunology 2004, 11:704-710.
29. Maubon D., Ajzenberg D., Brenier-Pinchart M.P., Darde M.L., Pelloux H. What are the respective host and parasite contributions to toxoplasmosis?. Trends in Parasitology 2008, 24(7):299-303.
30. Nam H.W. GRA proteins of Toxoplasma gondii: maintenance of host-parasite interactions across the parasitophorous vacuolar membrane. Korean Journal of Parasitology 2009, 47:S29-S37.
31. Ohno N., Suzuki M., Matsumoto T., Ohashi T., Murakami S., Ohta N. Strain difference of the immunostimulatory effect of CpG in OVA-sensitized mice. Nagoya Medical Journal 2005, 47:111-122.
32. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., Lambert L., Narum D.L., Wu Y., Saul A., Miller L.H., Long C.A., Mullen G.E. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26:2521-2527.
33. Saavedra R., Leyva R., Tenorio E.P., Haces M.L., Rodriguez-Sosa M., Terrazas L.I., Herion P. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii. Parasite Immunology 2004, 26:67-73.
34. Saeij J.P., Boyle J.P., Boothroyd J.C. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends in Parasitology 2005, 21:476-481.
35. Sayles P.C., Gibson G.W., Johnson L.L. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infection and Immunity 2000, 68:1026-1033.
36. Schaap D., Vermeulen A.N., Roberts C.W., Alexander J. Toxoplasma gondii. The Model Apicomplexan: Perspectives and Methods 2007, 721-759. Elsevier, Amsterdam. L.M. Weiss, K. Kim (Eds.).
37. Sher A., Wynn T.A., Sacks D.L. Fundamental Immunology 2003, 1171-1200. Lippincott Williams & Wilkins, Philadelphia. W.E. Paul (Ed.).
38. Spencer J.A., Smith B.F., Guarino A.J., Blagburn B.L., Baker H.J. The use of CpG as an adjuvant to Toxoplasma gondii vaccination. Parasitology Research 2004, 92:313-316.
39. Suzuki Y., Orellana M.A., Wong S.Y., Conley F.K., Remington J.S. Susceptibility to chronic infection with Toxoplasma gondii does not correlate with susceptibility to acute infection in mice. Infection and Immunity 1993, 61:2284-2288.
40. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. International Journal for Parasitology 2000, 30:1217-1258.
41. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:6970-6975.
42. Wild J., Grusby M.J., Schirmbeck R., Reimann J. Priming MHCI-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Journal of Immunology 1999, 163:1880-1887.
43. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Roècken M., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. Journal of Immunology 1998, 160:3627-3630.
44. Zimmermann S., Dalpke A., Heeg K. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. International Journal of Medical Microbiology 2008, 298:39-44.